Atrion (NASDAQ:ATRI) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Atrion (NASDAQ:ATRI) in a report released on Tuesday morning. The firm issued a sell rating on the medical instruments supplier’s stock.

Atrion Price Performance

Shares of NASDAQ:ATRI opened at $455.60 on Tuesday. Atrion has a 12 month low of $274.98 and a 12 month high of $593.00. The firm has a market capitalization of $801.86 million, a P/E ratio of 42.82 and a beta of 0.68. The company’s fifty day moving average price is $454.15 and its 200 day moving average price is $409.23.

Atrion (NASDAQ:ATRI) last posted its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 EPS for the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%. The business had revenue of $47.33 million for the quarter.

Atrion Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 14th were issued a $2.20 dividend. This represents a $8.80 annualized dividend and a dividend yield of 1.93%. The ex-dividend date was Friday, June 14th. Atrion’s payout ratio is currently 82.71%.

Hedge Funds Weigh In On Atrion

A number of institutional investors have recently modified their holdings of ATRI. Vanguard Group Inc. boosted its stake in Atrion by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 84,876 shares of the medical instruments supplier’s stock worth $39,344,000 after purchasing an additional 326 shares during the period. Boston Trust Walden Corp boosted its stake in shares of Atrion by 4.8% during the fourth quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock worth $13,292,000 after buying an additional 1,609 shares during the period. Penn Mutual Asset Management LLC purchased a new position in shares of Atrion during the fourth quarter worth about $1,949,000. Public Employees Retirement System of Ohio acquired a new position in Atrion in the 1st quarter valued at about $2,299,000. Finally, Citizens Financial Group Inc. RI purchased a new stake in Atrion during the 4th quarter valued at approximately $1,114,000. 66.19% of the stock is owned by institutional investors and hedge funds.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.